progesterone receptors

Summary

Summary: Specific proteins found in or on cells of progesterone target tissues that specifically combine with progesterone. The cytosol progesterone-receptor complex then associates with the nucleic acids to initiate protein synthesis. There are two kinds of progesterone receptors, A and B. Both are induced by estrogen and have short half-lives.

Top Publications

  1. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
  2. pmc American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    J Clin Oncol 28:2784-95. 2010
  3. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
  4. ncbi Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    D C Allred
    Department of Pathology, University of Texas Health Science Center, San Antonio 78284, USA
    Mod Pathol 11:155-68. 1998
  5. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
  6. pmc Genome-wide association study identifies novel breast cancer susceptibility loci
    Douglas F Easton
    CR UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
    Nature 447:1087-93. 2007
  7. ncbi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
  8. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
  9. ncbi Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    Manfred Kaufmann
    Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
    J Clin Oncol 24:1940-9. 2006
  10. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    Arch Pathol Lab Med 134:e48-72. 2010

Detail Information

Publications328 found, 100 shown here

  1. ncbi Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study
    Lisa A Carey
    Division of Hematology Oncology, School of Public Health, Department of Epidemiology, University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, NC 27599 7305, USA
    JAMA 295:2492-502. 2006
    ..Gene expression analysis has identified several breast cancer subtypes, including basal-like, human epidermal growth factor receptor-2 positive/estrogen receptor negative (HER2+/ER-), luminal A, and luminal B...
  2. pmc American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    J Clin Oncol 28:2784-95. 2010
    ..To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers...
  3. ncbi A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
    Soonmyung Paik
    Division of Pathology, Operation Center, and the Biostatistics Center, National Surgical Adjuvant Breast and Bowel Project, Pittsburgh 15212, USA
    N Engl J Med 351:2817-26. 2004
    ..The likelihood of distant recurrence in patients with breast cancer who have no involved lymph nodes and estrogen-receptor-positive tumors is poorly defined by clinical and histopathological measures...
  4. ncbi Prognostic and predictive factors in breast cancer by immunohistochemical analysis
    D C Allred
    Department of Pathology, University of Texas Health Science Center, San Antonio 78284, USA
    Mod Pathol 11:155-68. 1998
    ..Pathologists today, however, are evaluating estrogen and progesterone receptors almost exclusively by immunohistochemical means...
  5. ncbi Triple-negative breast cancer: clinical features and patterns of recurrence
    Rebecca Dent
    Department of Medical Oncology, Sunnybrook Health Sciences Center, University of Toronto, Ontario, Canada
    Clin Cancer Res 13:4429-34. 2007
    ..To compare the clinical features, natural history, and outcomes for women with "triple-negative" breast cancer with women with other types of breast cancer...
  6. pmc Genome-wide association study identifies novel breast cancer susceptibility loci
    Douglas F Easton
    CR UK Genetic Epidemiology Unit, Department of Public Health and Primary Care, University of Cambridge, Cambridge CB1 8RN, UK
    Nature 447:1087-93. 2007
    ..05 level compared with an estimated 1,343 that would be expected by chance, indicating that many additional common susceptibility alleles may be identifiable by this approach...
  7. ncbi Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer
    Cornelia Liedtke
    Department of Breast Medical Oncology, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030 1439, USA
    J Clin Oncol 26:1275-81. 2008
    ..In this study, we compared response to neoadjuvant chemotherapy and survival between patients with TNBC and non-TNBC...
  8. ncbi Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
    Yixin Wang
    Veridex LLC, a Johnson and Johnson Company, San Diego, CA, USA
    Lancet 365:671-9. 2005
    ....
  9. ncbi Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update
    Manfred Kaufmann
    Department of Obstetrics and Gynecology, J W Goethe University Hospital, Frankfurt, Germany
    J Clin Oncol 24:1940-9. 2006
    ..As part of this effort, data published to date were reviewed critically and indications for neoadjuvant treatment were newly defined...
  10. ncbi American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version)
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    Arch Pathol Lab Med 134:e48-72. 2010
    ..To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers...
  11. ncbi Locoregional relapse and distant metastasis in conservatively managed triple negative early-stage breast cancer
    Bruce G Haffty
    Department of Radiation Oncology, Cancer Institute of New Jersey, Robert Wood Johnson Medical School University of Medicine and Dentistry of New Jersey, New Brunswick, NJ 08903 2681, USA
    J Clin Oncol 24:5652-7. 2006
    ..To determine the prognostic significance of triple negative breast cancers with respect to locoregional relapse and distant metastasis in conservatively managed breast cancer patients...
  12. ncbi Mice lacking progesterone receptor exhibit pleiotropic reproductive abnormalities
    J P Lydon
    Department of Cell Biology, Baylor College of Medicine, Houston, Texas 77030, USA
    Genes Dev 9:2266-78. 1995
    ..Collectively, these results provide direct support for progesterone's role as a pleiotropic coordinator of diverse reproductive events that together ensure species survival...
  13. ncbi Sequence and characterization of a coactivator for the steroid hormone receptor superfamily
    S A Onate
    Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
    Science 270:1354-7. 1995
    ..Together, these results indicate that SRC-1 encodes a coactivator that is required for full transcriptional activity of the steroid receptor superfamily...
  14. ncbi The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes
    Lisa A Carey
    Division of Hematology Oncology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599 7305, USA
    Clin Cancer Res 13:2329-34. 2007
    ..Gene expression analysis identifies several breast cancer subtypes. We examined the relationship of neoadjuvant chemotherapy response to outcome among these breast cancer subtypes...
  15. ncbi Activating gene expression in mammalian cells with promoter-targeted duplex RNAs
    Bethany A Janowski
    Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390, USA
    Nat Chem Biol 3:166-73. 2007
    ..These data show that, like proteins, hormones and small molecules, small duplex RNAs interact at promoters and can activate or repress gene expression...
  16. ncbi Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry
    Katrina R Bauer
    Public Health Institute California Cancer Registry, Sacramento, California 95815 4402, USA
    Cancer 109:1721-8. 2007
    ..The triple-negative phenotype is important because of its relation to the basal-like subtype of breast cancer...
  17. ncbi Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA
    Mary Jo Lund
    Department of Epidemiology, Rollins School of Public Health, Emory University, 1518 Clifton Road, NE, Atlanta, GA 30322, USA
    Breast Cancer Res Treat 113:357-70. 2009
    ..This study examines association of the ER/PR/HER2 subtypes with race and breast cancer survival...
  18. pmc Progesterone receptors: form and function in brain
    Roberta Diaz Brinton
    Department of Pharmacology and Pharmaceutical Sciences, University of Southern California, School of Pharmacy, 1985 Zonal Avenue, Los Angeles, CA 90089, USA
    Front Neuroendocrinol 29:313-39. 2008
    ..Progesterone-regulated neural responses are mediated by an array of progesterone receptors (PR) that include the classic nuclear PRA and PRB receptors and splice variants of each, the seven ..
  19. ncbi Etiology of hormone receptor-defined breast cancer: a systematic review of the literature
    Michelle D Althuis
    Hormonal and Reproductive Epidemiology Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, Room 7084, 6120 Executive Boulevard, Rockville, MD 20852, USA
    Cancer Epidemiol Biomarkers Prev 13:1558-68. 2004
    ..Large population-based studies of determinants of hormone receptor-defined breast cancers defined using state-of-the-art quantitative immunostaining methods are needed to clarify the role of ER/PR expression in breast cancer etiology...
  20. ncbi PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma
    Lao H Saal
    Integrated Program in Cellular, Molecular, and Biophysical Studies, Institute for Cancer Genetics, College of Physicians and Surgeons, Columbia University, New York, New York 10032, USA
    Cancer Res 65:2554-9. 2005
    ..In addition, PIK3CA mutations were associated with expression of estrogen and progesterone receptors (ER/PR), lymph node metastasis, and ERBB2 overexpression...
  21. pmc Gene expression profiling and histopathological characterization of triple-negative/basal-like breast carcinomas
    Bas Kreike
    Division of Radiation Oncology, The Netherlands Cancer Institute, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res 9:R65. 2007
    ..We examined the histopathological and gene-expression profile of triple-negative tumors to define subgroups with specific characteristics, including risk of developing distant metastases...
  22. ncbi Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study
    Bella Kaufman
    Chaim Sheba Medical Center, Tel Hashomer, Israel
    J Clin Oncol 27:5529-37. 2009
    ..TAnDEM is the first randomized phase III study to combine a hormonal agent and trastuzumab without chemotherapy as treatment for human epidermal growth factor receptor 2 (HER2)/hormone receptor-copositive metastatic breast cancer (MBC)...
  23. ncbi Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases
    V Boonyaratanakornkit
    University of Colorado School of Medicine, Pathology Department and Molecular Biology Program, Denver, CO 80262, USA
    Mol Cell 8:269-80. 2001
    ....
  24. pmc Use of immunohistochemical markers can refine prognosis in triple negative breast cancer
    Marc Tischkowitz
    Program in Cancer Genetics, McGill University, Montreal, Quebec, Canada
    BMC Cancer 7:134. 2007
    ..The IHC pattern that best defines basal-like tumors is under investigation and various combinations of ER, PR, HER2-, CK5/6+ and EGFR+ have been tested...
  25. ncbi Progesterone receptor membrane component 1: an integrative review
    Michael A Cahill
    ProteoSys AG, Carl Zeiss Str 51, 55129 Mainz, Germany
    J Steroid Biochem Mol Biol 105:16-36. 2007
    ..Evidence for roles in disease, especially cancer, is also discussed...
  26. ncbi Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy
    Xiaojiang Cui
    Breast Center, Baylor College of Medicine, Houston, TX 77030, USA
    J Clin Oncol 23:7721-35. 2005
    ..Finally, we will consider the clinical implications of these observations...
  27. ncbi Label-retaining epithelial cells in mouse mammary gland divide asymmetrically and retain their template DNA strands
    Gilbert H Smith
    Laboratory of Mammary Gland Biology and Tumorigenesis, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA
    Development 132:681-7. 2005
    ....
  28. ncbi Basal-like breast cancer defined by five biomarkers has superior prognostic value than triple-negative phenotype
    Maggie C U Cheang
    Genetic Pathology Evaluation Centre, Vancouver Coastal Health Research Institute, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Clin Cancer Res 14:1368-76. 2008
    ..This study directly compares the prognostic significance between three- and five-biomarker surrogate panels to define intrinsic breast cancer subtypes, using a large clinically annotated series of breast tumors...
  29. ncbi Triple-negative breast cancer: therapeutic options
    Susan Cleator
    Oncology Department, St Mary s Hospital Trust, London, UK
    Lancet Oncol 8:235-44. 2007
    ....
  30. ncbi Nuclear progesterone receptors in the human pregnancy myometrium: evidence that parturition involves functional progesterone withdrawal mediated by increased expression of progesterone receptor-A
    Amy A Merlino
    Department of Reproductive Biology, Case Western Reserve University, 11100 Euclid Avenue, Cleveland, OH 44106 5034, USA
    J Clin Endocrinol Metab 92:1927-33. 2007
    We examined whether human parturition involves functional progesterone withdrawal mediated by changes in myometrial expression of progesterone receptors (PRs)-A and -B.
  31. ncbi Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells
    Jennifer K Richer
    Department of Medicine Endocrinology, University of Colorado School of Medicine, Denver, Colorado 80262, USA
    J Biol Chem 277:5209-18. 2002
    The PR-A and PR-B isoforms of progesterone receptors (PR) have different physiological functions, and their ratio varies widely in breast cancers...
  32. pmc The role of oestrogen and progesterone receptors in human mammary development and tumorigenesis
    Elizabeth Anderson
    Tumour Biochemistry Laboratory, Christie Hospital NHS Trust, Manchester, UK
    Breast Cancer Res 4:197-201. 2002
    ....
  33. ncbi Dissociation between steroid receptor expression and cell proliferation in the human breast
    R B Clarke
    Clinical Research Department, University of Manchester Christie Hospital National Health Service Trust, United Kingdom
    Cancer Res 57:4987-91. 1997
    ..This organization may be disrupted in some tumors...
  34. ncbi Prognostic markers in triple-negative breast cancer
    Emad A Rakha
    Department of Histopathology, Molecular Medical Sciences, University of Nottingham, Nottingham, United Kingdom
    Cancer 109:25-32. 2007
    ..Triple-negative breast cancer (estrogen receptor-negative, progesterone receptor-negative, and HER2-negative) is a high risk breast cancer that lacks the benefit of specific therapy that targets these proteins...
  35. pmc American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer
    M Elizabeth H Hammond
    Intermountain Healthcare, University of Utah School of Medicine, Salt Lake City, UT, USA
    Arch Pathol Lab Med 134:907-22. 2010
    ..To develop a guideline to improve the accuracy of immunohistochemical (IHC) estrogen receptor (ER) and progesterone receptor (PgR) testing in breast cancer and the utility of these receptors as predictive markers...
  36. ncbi Immunohistochemistry of estrogen and progesterone receptors reconsidered: experience with 5,993 breast cancers
    Mehrdad Nadji
    Department of Pathology, University of Miami Jackson Memorial Hospital, FL 33136, USA
    Am J Clin Pathol 123:21-7. 2005
    ..ER positivity and negativity are predictable in certain histologic types and nuclear grades of breast cancer. The reaction for PR can be heterogeneous or focal...
  37. ncbi Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
    Gottfried Konecny
    Division of Hematology Oncology, Department of Medicine, and Jonsson Comprehensive Cancer Center, University of California at Los Angeles School of Medicine, Los Angeles 90095 1678, USA
    J Natl Cancer Inst 95:142-53. 2003
    ..To better understand the relationship between HER-2/neu positivity and HR expression, we analyzed HER-2/neu, ER, and PR as continuous variables in breast cancer cell lines and two cohorts of primary breast cancer patients...
  38. ncbi Non-genomic progesterone actions in female reproduction
    B Gellersen
    Endokrinologikum Hamburg, Hamburg, Germany
    Hum Reprod Update 15:119-38. 2009
    ..In addition to activating the progesterone receptors (PRs)-B and -A, members of the superfamily of ligand-dependent transcription factors, progesterone also ..
  39. pmc Identification, classification, and partial characterization of genes in humans and other vertebrates homologous to a fish membrane progestin receptor
    Yong Zhu
    Marine Science Institute, University of Texas at Austin, 750 Channel View Drive, Port Aransas, TX 78373, USA
    Proc Natl Acad Sci U S A 100:2237-42. 2003
    ..These results suggest this is a new family of steroid receptors unrelated to nuclear steroid receptors, but instead having characteristics of G protein-coupled receptors...
  40. ncbi Biologic and clinical characteristics of breast cancer with single hormone receptor positive phenotype
    Emad A Rakha
    Department of Histopathology and Surgery, School of Molecular Medical Sciences, Nottingham University Hospitals National Health Service Trust and University of Nottingham, Nottingham, United Kingdom
    J Clin Oncol 25:4772-8. 2007
    ..It is usually easier to decide treatment strategies in cases of double-positive/-negative phenotypes than in single-positive tumors...
  41. pmc Comparison of molecular phenotypes of ductal carcinoma in situ and invasive breast cancer
    Rulla M Tamimi
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 181 Longwood Avenue, Boston, MA, 02115, USA
    Breast Cancer Res 10:R67. 2008
    ..The purpose of this study was to compare the prevalence of these distinct molecular subtypes among cases of DCIS and invasive breast cancer...
  42. pmc Comparative analysis of the influence of the high-mobility group box 1 protein on DNA binding and transcriptional activation by the androgen, glucocorticoid, progesterone and mineralocorticoid receptors
    Guy Verrijdt
    Division of Biochemistry, Faculty of Medicine, Catholic University of Leuven, Herestraat 49, B 3000 Leuven, Belgium
    Biochem J 361:97-103. 2002
    ..transfection assays, however, HMGB1 significantly enhances the activity of the glucocorticoid and progesterone receptors but not the androgen or mineralocorticoid receptor...
  43. ncbi c-Src and cooperating partners in human cancer
    Rumey Ishizawar
    Cancer Center and Department of Microbiology, University of Virginia Health System, P O Box 800734, Charlottesville, VA 22908, USA
    Cancer Cell 6:209-14. 2004
    ..Because of its important role in these oncogenic processes, it represents a therapeutic target ripe for exploitation...
  44. ncbi Reproductive phenotpes of the progesterone receptor null mutant mouse
    J P Lydon
    Departement of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA
    J Steroid Biochem Mol Biol 56:67-77. 1996
    ....
  45. ncbi Candidates for membrane progestin receptors--past approaches and future challenges
    Yong Zhu
    Department of Biology, East Carolina University, 1000 E 5th Street, Greenville, NC 27858, USA
    Comp Biochem Physiol C Toxicol Pharmacol 148:381-9. 2008
    ..Clarification of the controversies surrounding the identities and localization of membrane progestin receptors may help direct future research that could advance our understanding of rapid actions of steroids...
  46. pmc Heterologous expression of human mPRalpha, mPRbeta and mPRgamma in yeast confirms their ability to function as membrane progesterone receptors
    Jessica L Smith
    Department of Chemistry, University of Florida, P O Box 117200, Gainesville, FL 32611, United States
    Steroids 73:1160-73. 2008
    ..These results strongly suggest that these receptors may indeed function as the long-sought-after membrane progesterone receptors. Additionally, we show that two uncharacterized PAQRs, PAQR6 and PAQR9, are also capable of responding to ..
  47. ncbi Steroid receptor coactivator (SRC)-1 and SRC-3 differentially modulate tissue-specific activation functions of the progesterone receptor
    Sang Jun Han
    Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, Texas 77030, USA
    Mol Endocrinol 20:45-55. 2006
    ..SRC-3 is the primary coactivator for PR in breast and SRC-1 is the primary coactivator for PR in uterus...
  48. pmc Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies
    Huiyan Ma
    Department of Preventive Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, 1441 Eastlake Avenue 4407, Los Angeles, CA 90089, USA
    Breast Cancer Res 8:R43. 2006
    ..This report presents the first meta-analysis of results from epidemiological studies that have investigated parity, age at first birth, breastfeeding, and age at menarche in relation to ER+PR+ and ER-PR- cancer risk...
  49. ncbi Molecular subtyping of breast cancer from traditional tumor marker profiles using parallel clustering methods
    Federico Ambrogi
    Unit of Medical Statistics and Biometry, National Cancer Institute of Milano, Milan, Italy
    Clin Cancer Res 12:781-90. 2006
    ..Thus, we sought to identify distinct tumor profiles with possible clinical relevance based on clusters of immunohistochemical molecular markers measured on a large, single institution, case series...
  50. ncbi CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup
    Angela Bowman
    Imperial Cancer Research Fund Medical Oncology Unit, Western General Hospital, Edinburgh EH4 2XU, United Kingdom
    Clin Cancer Res 8:2233-9. 2002
    ..This study was an open-label Phase II trial of the aromatase inhibitor letrozole (Femara) in patients with relapsed ovarian cancer with evaluation of possible biological markers for response...
  51. ncbi Promoter hypermethylation of TMS1, BRCA1, ERalpha and PRB in serum and tumor DNA of invasive ductal breast carcinoma patients
    Sameer Mirza
    Department of Biochemistry, All India Institute of Medical Sciences, Ansari Nagar, New Delhi 110029, India
    Life Sci 81:280-7. 2007
    ..This study also underscores the potential utility of DNA methylation based screening of serum (a surrogate for tumor DNA methylation) as a tool for detection of breast cancer...
  52. pmc Protein kinases mediate ligand-independent derepression of sumoylated progesterone receptors in breast cancer cells
    Andrea R Daniel
    Department of Medicine, Division of Hematology, University of Minnesota Masonic Cancer Center, Minneapolis, MN 55455, USA
    Proc Natl Acad Sci U S A 106:14287-92. 2009
    ..Our data explain why breast cancer models often remain insensitive to progestins, but are growth-inhibited by antiprogestins, and underscore the need to target PR-B and associated kinase activities as part of breast cancer therapy...
  53. ncbi Membrane progesterone receptors localization in the mouse spinal cord
    F Labombarda
    UMR788 Inserm and University Paris Sud 11, Kremlin Bicetre, France
    Neuroscience 166:94-106. 2010
    ..expression, which was similar in both sexes and not influenced by the presence or absence of the classical progesterone receptors. Although mPRgamma mRNA could be detected in spinal cord tissue by reverse transcriptase-polymerase chain ..
  54. pmc Defective mammary gland morphogenesis in mice lacking the progesterone receptor B isoform
    Biserka Mulac-Jericevic
    Department of Molecular and Cellular Biology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
    Proc Natl Acad Sci U S A 100:9744-9. 2003
    ....
  55. pmc ALU repeats in promoters are position-dependent co-response elements (coRE) that enhance or repress transcription by dimeric and monomeric progesterone receptors
    Britta M Jacobsen
    Department of Medicine Endocrinology, University of Colorado Denver, Anschutz Medical Campus, Aurora, Colorado 80045, USA
    Mol Endocrinol 23:989-1000. 2009
    ..We propose that in natural promoters the coRE functions as a composite response element with imperfect PRE and half-sites to present variable, orientation-dependent transcription factors for interaction with nearby PR...
  56. ncbi FOXA1 expression in breast cancer--correlation with luminal subtype A and survival
    Sunil Badve
    Department of Pathology, Indiana University School of Medicine, Indianapolis, USA
    Clin Cancer Res 13:4415-21. 2007
    ..It segregates with genes that characterize the luminal subtypes in DNA microarray analyses. The utility of FOXA1 as a possible independent prognostic factor has not been determined in breast cancers...
  57. ncbi Rates for breast cancer characteristics by estrogen and progesterone receptor status in the major racial/ethnic groups
    Kenneth C Chu
    Center to Reduce Cancer Health Disparities, National Cancer Institute, Bethesda, MD 20892 8341, USA
    Breast Cancer Res Treat 74:199-211. 2002
    ....
  58. pmc Antisense transcripts are targets for activating small RNAs
    Jacob C Schwartz
    Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9041, USA
    Nat Struct Mol Biol 15:842-8. 2008
    ..Our data demonstrate that antisense transcripts have a central role in recognition of the PR promoter by both activating and inhibitory agRNAs...
  59. ncbi Cloning and characterization of human prostate coactivator ARA54, a novel protein that associates with the androgen receptor
    H Y Kang
    George Whipple Lab for Cancer Research, Departments of Pathology, Urology, and Radiation Oncology and the Cancer Center, University of Rochester Medical Center, Rochester, New York 14642, USA
    J Biol Chem 274:8570-6. 1999
    ..Through our findings, we have identified and characterized a novel AR coactivator, ARA54, which may play an important role in the AR signaling pathway in human prostate...
  60. ncbi p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma
    B Linderholm
    Department of Oncology, Umea University, Sweden
    Int J Cancer 89:51-62. 2000
    ..Combination of these 2 biological markers appears to give additional predictive information of survival. A high-risk group of patients was associated with p53 positivity and higher VEGF content...
  61. ncbi Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up
    Lisa Rydén
    Department of Surgery, Helsingborgs lasarett, SE 251 85 Helsingborg, Sweden
    Eur J Cancer 41:256-64. 2005
    ..PR status was a significant predictor of response to tamoxifen in multivariate models with testing of interactions of hormone receptor status and adjuvant therapy...
  62. ncbi Ductal carcinoma in situ with basal-like phenotype: a possible precursor to invasive basal-like breast cancer
    Bradley B Bryan
    Department of Pathology, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, MA 02215, USA
    Mod Pathol 19:617-21. 2006
    ....
  63. ncbi Relationship of estrogen and progesterone receptors to clinical outcome in metastatic endometrial carcinoma: a Gynecologic Oncology Group Study
    Meenakshi Singh
    Department of Pathology, The University of Colorado Health Sciences Center, Denver, CO 80262, United States
    Gynecol Oncol 106:325-33. 2007
    ..The goal of this study was to explore the relationship between the expression of hormone receptors in metastatic endometrial tumors and clinical response to daily tamoxifen citrate and intermittent weekly medroxyprogesterone acetate...
  64. pmc Clinical correlates of low-risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident breast cancer cases
    Petra E A Huijts
    Department of Clinical Genetics, K5 R, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands
    Breast Cancer Res 9:R78. 2007
    ..Seven SNPs in five genomic loci were recently found to confer a mildly increased risk of breast cancer...
  65. pmc High aromatase expression in uterine leiomyoma tissues of African-American women
    Hiroshi Ishikawa
    Division of Reproductive Biology Research, Robert H Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL 60611, USA
    J Clin Endocrinol Metab 94:1752-6. 2009
    ..African-American women develop uterine leiomyomas at an earlier age and with higher frequency compared with Caucasian-American women or other races; however, the underlying mechanism for this discrepancy is unknown...
  66. ncbi Carcinoma-associated fibroblasts activate progesterone receptors and induce hormone independent mammary tumor growth: A role for the FGF-2/FGFR-2 axis
    Sebastián Giulianelli
    Laboratory of Hormonal Carcinogenesis, Institute of Experimental Biology and Medicine IBYME National Research Council of Argentina CONICET, Buenos Aires, Argentina
    Int J Cancer 123:2518-31. 2008
    ..FGF-2 activated the progesterone receptors (PR) in the tumor cells, thus increasing cell proliferation in both HI and HD tumors...
  67. ncbi Association between sulfotransferase 1A1 genotype and survival of breast cancer patients receiving tamoxifen therapy
    Susan Nowell
    S Nowell, Department of Pharmacology and Toxicology, University of Arkansas for Medical Sciences, Little Rock, USA
    J Natl Cancer Inst 94:1635-40. 2002
    ..We investigated the hypothesis that that high sulfation activity would increase the elimination of 4-OH TAM by examining whether the presence of this polymorphism affects the efficacy of tamoxifen therapy...
  68. ncbi The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer
    Claudia Lanari
    Laboratory of Hormonal Carcinogenesis, Instituto de Biología y Medicina Experimental IBYME Consejo Nacional de Investigaciones Científicas y Técnicas CONICET, C1428ADN, Buenos Aires, CF, Argentina
    Endocr Relat Cancer 16:333-50. 2009
    More than 60% of all breast neoplasias are ductal carcinomas expressing estrogen (ER) and progesterone receptors (PR)...
  69. ncbi Loss of nuclear p16 protein expression is not associated with promoter methylation but defines a subgroup of aggressive endometrial carcinomas with poor prognosis
    H B Salvesen
    Department of Pathology, The Gade Institute, Haukeland University Hospital, Bergen, Norway
    Clin Cancer Res 6:153-9. 2000
    ..Methylation of the promoter region seems to be an uncommon mechanism of p16 inactivation in endometrial carcinoma...
  70. pmc Prognostic significance of TP53 alterations in breast carcinoma
    T I Andersen
    Department of Genetics, Norwegian Radium Hospital, Oslo
    Br J Cancer 68:540-8. 1993
    ..Furthermore, there were statistically significant associations, independent of other prognostic factors, between TP53 alterations in primary tumour and disease-free and overall survival...
  71. ncbi Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older
    Christopher I Li
    Fred Hutchinson Cancer Research Center, Division of Public Health Sciences, Seattle, Washington 98109 1024, USA
    Cancer Epidemiol Biomarkers Prev 11:601-7. 2002
    ..Understanding the factors underlying these differences may provide further insight into breast cancer etiology in different populations...
  72. pmc ERalpha-negative and triple negative breast cancer: molecular features and potential therapeutic approaches
    Jin Qiang Chen
    Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Biochim Biophys Acta 1796:162-75. 2009
    ..cancer (TNBC) is a type of aggressive breast cancer lacking the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor-2 (HER-2)...
  73. ncbi Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 25:3846-52. 2007
    ..To evaluate locally versus centrally assessed estrogen (ER) and progesterone (PgR) receptor status and the impact of PgR on letrozole adjuvant therapy compared with tamoxifen in postmenopausal women with early breast cancer...
  74. ncbi Cyclic AMP and progesterone receptor cross-talk in human endometrium: a decidualizing affair
    B Gellersen
    IHF Institute for Hormone and Fertility Research, University of Hamburg, Hamburg, Germany
    J Endocrinol 178:357-72. 2003
    ....
  75. pmc Determination of HER2 status using both serum HER2 levels and circulating tumor cells in patients with recurrent breast cancer whose primary tumor was HER2 negative or of unknown HER2 status
    Tanja Fehm
    Department of Obstetrics and Gynecology, University of Tuebingen, Calwerstrasse, D 72076 Tuebingen, Germany
    Breast Cancer Res 9:R74. 2007
    ..The aim of this study was therefore to determine the HER2 status in serum and corresponding CTCs in patients with metastatic breast cancer whose primary tumors were HER2 negative or of unknown HER2 status...
  76. ncbi Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy
    Paul L Nguyen
    Department of Radiation Oncology, Massachusetts General Hospital, Boston, MA, USA
    J Clin Oncol 26:2373-8. 2008
    ..To determine whether breast cancer subtype is associated with outcome after breast-conserving therapy (BCT) consisting of lumpectomy and radiation therapy...
  77. ncbi Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer
    Hyun Jung Kim
    Breast Center, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
    Clin Cancer Res 12:1013s-1018s. 2006
    ....
  78. ncbi Immunohistochemical and molecular subtypes of breast cancer in Nigeria
    Clement A Adebamowo
    Division of Oncology, Department of Surgery, College of Medicine, University of Ibadan, University College Hospital, Ibadan, Oyo State, Nigeria
    Breast Cancer Res Treat 110:183-8. 2008
    ..We decided to evaluate the hormone receptor status of patients seen in our practice to see if they indeed differ from that of other populations...
  79. pmc Cochaperone immunophilin FKBP52 is critical to uterine receptivity for embryo implantation
    Susanne Tranguch
    Departments of Pediatrics, Cell and Developmental Biology, Cancer Biology, and Pharmacology, Vanderbilt University Medical Center, Nashville, TN 37232, USA
    Proc Natl Acad Sci U S A 102:14326-31. 2005
    ..Collectively, the present investigation provides evidence for an in vivo role for this cochaperone in regulating tissue-specific hormone action and its critical role in uterine receptivity for implantation...
  80. pmc High-mobility group chromatin proteins 1 and 2 functionally interact with steroid hormone receptors to enhance their DNA binding in vitro and transcriptional activity in mammalian cells
    V Boonyaratanakornkit
    Department of Pathology and Molecular Biology Program, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    Mol Cell Biol 18:4471-87. 1998
    ....
  81. pmc A paracrine role for the epithelial progesterone receptor in mammary gland development
    C Brisken
    Whitehead Institute for Biomedical Research and Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02142, USA
    Proc Natl Acad Sci U S A 95:5076-81. 1998
    ....
  82. ncbi Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer
    Stephen Johnston
    Royal Marsden Hospital, London, United Kingdom
    J Clin Oncol 27:5538-46. 2009
    ....
  83. ncbi WW domain binding protein-2, an E6-associated protein interacting protein, acts as a coactivator of estrogen and progesterone receptors
    Sarath C Dhananjayan
    Department of Biochemistry and Molecular Biology, University of Miami School of Medicine, Miami, Florida 33136, USA
    Mol Endocrinol 20:2343-54. 2006
    ..Taken together, our data establish the role of WBP-2 and YAP as coactivators for ER and PR transactivation pathways...
  84. ncbi Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
    M Dowsett
    Academic Department of Biochemistry, The Royal Marsden NHS Trust, London, UK
    Ann Oncol 17:818-26. 2006
    ..The measurement of tumour biomarkers should allow better selection of patients for such treatment or for therapies such as aromatase inhibitors...
  85. ncbi A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
    Michele De Laurentiis
    Dipartimento di Endocrinologia ed Oncologia Molecolare e Clinica, Universita Federico II, Napoli, Italy
    Clin Cancer Res 11:4741-8. 2005
    ..Clinical data, however, have been conflicting. We have conducted a meta-analysis on the interaction between the response to endocrine treatment and the overexpression of HER-2 in metastatic breast cancer...
  86. ncbi The 70-gene signature as a response predictor for neoadjuvant chemotherapy in breast cancer
    Marieke E Straver
    Department of Surgical Oncology, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX Amsterdam, The Netherlands
    Breast Cancer Res Treat 119:551-8. 2010
    ..023). A pCR is unlikely to be achieved in tumors that have a good prognosis-signature. Tumors with a poor prognosis-signature are more sensitive to chemotherapy...
  87. ncbi Anxiolytic activity of progesterone in progesterone receptor knockout mice
    Doodipala S Reddy
    Department of Molecular Biomedical Sciences, North Carolina State University College of Veterinary Medicine, 4700 Hillsborough Street, Raleigh, NC 27606, USA
    Neuropharmacology 48:14-24. 2005
    ..Progesterone regulates reproductive behavior by activating intracellular progesterone receptors (PRs)...
  88. ncbi Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis
    Reiko Suzuki
    Institute of Environmental Medicine, Division of Nutritional Epidemiology, Karolinska Institutet, Stockholm, Sweden
    Int J Cancer 124:698-712. 2009
    ..The relation between body weight and breast cancer risk is critically dependent on the tumor's ER/PR status and the woman's menopausal status. Body weight control is the effective strategy for preventing ER+PR+ tumors after menopause...
  89. ncbi Steroid hormone receptors and long term survival in invasive ovarian cancer
    K Münstedt
    Department of Gynecology, Gynecological Endocrinology and Gynecological Oncology, Philipps University Marburg, Marburg, Germany
    Cancer 89:1783-91. 2000
    ....
  90. pmc Hormone-dependent effects of FGFR2 and MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal African-American and European-American women
    Timothy R Rebbeck
    Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA
    Carcinogenesis 30:269-74. 2009
    ..We further report that these genes confer their effects in HER2- tumors, interact with one another to confer breast cancer susceptibility in AA women and interact with hormone exposures in AA and EA women...
  91. ncbi Estrogen receptor alpha pathway is involved in the regulation of Calbindin-D9k in the uterus of immature rats
    Geun Shik Lee
    Laboratory of Veterinary Biochemistry and Molecular Biology, College of Veterinary Medicine, Chungbuk National University, Cheongju, Chungbuk, 361 763 Republic of Korea
    Toxicol Sci 84:270-7. 2005
    ..Taken together, these results indicate that uterine CaBP-9k is induced by E2 and endocrine disrupting chemicals via the ERalpha pathway, but not ERbeta, in the uterus of immature rats...
  92. ncbi Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas)
    Enrique Lerma
    Department of Pathology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Mod Pathol 20:1200-7. 2007
    Basal breast carcinomas triple negative for estrogen receptors, progesterone receptors and Her2/neu breast carcinomas are more aggressive than conventional neoplasms...
  93. ncbi The N-terminal region of the human progesterone A-receptor. Structural analysis and the influence of the DNA binding domain
    D L Bain
    Department of Medicine and Molecular Biology Program, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Biol Chem 275:7313-20. 2000
    ..Microsequencing reveals that protease-accessible regions are limited to previously identified phosphorylation motifs and to functional domain boundaries...
  94. ncbi Expression of progesterone receptor is a favorable prognostic marker in ovarian cancer
    Peng Lee
    Department of Pathology, New York University Medical Center, New York, NY 10003, USA
    Gynecol Oncol 96:671-7. 2005
    ..We therefore examined the pattern of expression of ERs, PRs, and ARs in a large number of samples of primary ovarian carcinoma by using a tissue microarray technique...
  95. ncbi Prognostic and predictive factors in breast cancer
    N J Bundred
    South Manchester University Hospital, Manchester
    Cancer Treat Rev 27:137-42. 2001
    ..The use of hormone therapy and chemotherapy has been aided by factors predicting the likelihood of response, e.g. oestrogen receptor status. The value of newer prognostic and predictive markers is addressed...
  96. ncbi Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group
    Giuseppe Viale
    Division of Pathology and Laboratory Medicine, European Institute of Oncology, University of Milan, Milan, Italy
    J Clin Oncol 26:1404-10. 2008
    ....
  97. pmc Estrogen receptor-alpha and progesterone receptor are expressed in label-retaining mammary epithelial cells that divide asymmetrically and retain their template DNA strands
    Brian W Booth
    Mammary Biology and Tumorigenesis Laboratory, National Cancer Institute, National Institute of Health, Bethesda, Maryland, USA
    Breast Cancer Res 8:R49. 2006
    ..Mouse mammary epithelium contains label-retaining epithelial cells that divide asymmetrically and retain their template DNA...
  98. ncbi Alcohol exposure and breast cancer: results of the women's contraceptive and reproductive experiences study
    Jill A McDonald
    National Center for Chronic Disease Prevention and Health Promotion, Division of Reproductive Health, 4770 Buford Highway Northeast, MS K22, Atlanta, GA 30341 3724, USA
    Cancer Epidemiol Biomarkers Prev 13:2106-16. 2004
    ..To explore associated biological outcomes and clarify the role of timing of exposure in the alcohol-breast cancer relationship...
  99. ncbi Pattern of distribution of cells positive for estrogen receptor alpha and progesterone receptor in relation to proliferating cells in the mammary gland
    J Russo
    Breast Cancer Research Laboratory, Fox Chase Cancer Center, Philadelphia, PA 19111, USA
    Breast Cancer Res Treat 53:217-27. 1999
    ....
  100. ncbi Antiproliferative effects of progesterone antagonists and progesterone receptor modulators on the endometrium
    K Chwalisz
    Jenapharm GmbH and Co KG, Otto Schott Strasse 15, 077545, Jena
    Steroids 65:741-51. 2000
    ..Hence, the properties of PAs and PRMs (mesoprogestins) open up new applications in gynecological therapy and hormone replacement therapy...
  101. pmc Toll-like receptor-4-mediated macrophage activation is differentially regulated by progesterone via the glucocorticoid and progesterone receptors
    Leigh A Jones
    Strathclyde Institute for Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK
    Immunology 125:59-69. 2008
    ..by all three steroids, indicating that ligation by progesterone of either the glucocorticoid or the progesterone receptors or both could mediate this effect...

Research Grants71

  1. Physiology of Hypothalamic Neurosteroidal Progesterone
    Paul E Micevych; Fiscal Year: 2013
    ..This type of infertility exhibits excess estrogen production without ovulation that can lead to polycystic ovary syndrome, irregular vaginal bleeding, metabolic abnormalities as well as endometrial polyps, hyperplasia, and even cancer. ..
  2. Developing miRNA diagnostic methods and identifying tumor regulatory networks
    Thomas Tuschl; Fiscal Year: 2010
    ....
  3. Endocrine Targets for Prevention of Lung Cancer
    Robert M Bigsby; Fiscal Year: 2012
    ..These minimal studies will pave the way for testing receptor specific estrogen antagonists and additional PR-specific antagonists in prevention of tumor growth and progression in the lung. ..
  4. RCT of exercise on aromatase inhibitor side effects in breast cancer survivors
    Melinda L Irwin; Fiscal Year: 2012
    ..provided by applicant): Two thirds of all breast cancers diagnosed in US women express estrogen and/or progesterone receptors. Although 5 years of tamoxifen had long been the standard adjuvant hormonal therapy for women with early- ..
  5. microRNAs as novel biomarkers for management of breast cancer
    LORENZO SEMPERE; Fiscal Year: 2012
    ..Our results should provide a solid foundation to develop miRNA-based clinical assays to assist physicians in making crucial decisions with regards to treatment of patients. ..
  6. Genomic actions of progesterone receptors in human myometrial cells
    Sam Mesiano; Fiscal Year: 2010
    ..control of labor and in particular how the steroid hormone progesterone acting through the nuclear progesterone receptors (nPRs) PR-A and PR-B, controls uterine contractility...
  7. Exercise, Breast Cancer Prevention, and Mechanisms
    Henry J Thompson; Fiscal Year: 2013
    ..The data obtained has the potential to facilitate the translation of pre-clinical and clinical research to public health guidelines for PA directed to cancer prevention and control. ..
  8. Steroid-Based Contrast Agents for Magnetic Resonance Imaging of Endocrine Disease
    Thomas J Meade; Fiscal Year: 2013
    ..Gd)-conjugated progesterone derivatives as compounds capable of traversing the cell membrane, binding to progesterone receptors, initiating gene transcription, and enhancing contrast in mammalian tissues and tumors imaged in vivo ..
  9. Inhibiting EGFR and ER pathways in NSCLC
    Edward B Garon; Fiscal Year: 2013
    ..At the conclusion of this research training, I will be well positioned to function as an independent physician scientist in patient-oriented lung cancer research, and I anticipate competing for independent research funding. ..
  10. Regulation and Function of the Rhox8 homeobox gene in granulosa cells
    JAMES ARTHUR MACLEAN; Fiscal Year: 2010
    ....
  11. PROGESTERONE RECEPTOR AND ACTION IN THE PRIMATE OVARY
    Richard L Stouffer; Fiscal Year: 2013
    ....
  12. Integration of PR and FoxO Signaling in Pituitary Gonadotropes
    Varykina G Thackray; Fiscal Year: 2010
    ....
  13. Role of the Sex Hormones and Insulin/IGF-Axes in Endometrial Cancer Recurrence
    Howard D Strickler; Fiscal Year: 2012
    ..The study will be conducted in a large, prospective cohort study of endometrial cancer (GOG-0210). ..
  14. Fatty Acid Synthase:Molecular Target for Breast Cancer Therapy &Chemoprevention
    Ruth Lupu; Fiscal Year: 2013
    ..This proposal will provide new insight into the action of FASN inhibitors and the information needed to translate our findings into the clinic. Our goal is to develop novel rationally designed therapeutic approaches for breast cancer. ..
  15. BRCA1 and progesterone receptors in breast cancer
    Eva Y Lee; Fiscal Year: 2013
    ..A cross interaction between BRCA1 and nuclear hormone receptors including estrogen and progesterone receptors provides a potential window to address the tissue (mammary epithelial cells)-specific issue...
  16. Molecular Analysis of NeoAdjuvant Platinum in Triple Negative Breast Cancer
    MARK DANIEL contact PEGRAM; Fiscal Year: 2010
    ..copy number variation associated with pathologic (pCR) and clinical complete response (cCR), in patients with TNBC treated with neoadjuvant platinum-based chemotherapy, in order to identify robust biomarkers for response prediction ..
  17. Modifiable lifestyle-related factors and triple negative breast cancer prognosis
    SARAH JEAN NECHUTA; Fiscal Year: 2013
    ..Further, the proposed project will help sustain collaborative research efforts to promote future pooled analyses in the ABCPP. ..
  18. HORMONAL INFLUENCES ON AIRWAY DISEASE
    Raksha Jain; Fiscal Year: 2013
    ..These findings could lead to novel therapeutic approaches involving inhaled hormone manipulation in patients with bronchiectasis and other airway diseases such as asthma and chronic obstructive pulmonary disease. ..
  19. Defining the CD44-STAT3 axis in the pathogenesis of triple-negative breast cancer
    JENNIFER ELYNN YEH; Fiscal Year: 2013
    ..Furthermore, increased understanding of the CD44 signaling pathway may ultimately provide clues about how other cancer surface markers are involved in tumorigenesis. ..
  20. A Novel IgE Cancer Therapeutic Specific for the Epithelial Membrane Protein-2
    TRACY RUTH DANIELS-WELLS; Fiscal Year: 2013
    ..Given the high expression of EMP2 on a number of malignancies, these studies will be important to establish the anti-EMP2 IgE as a potential therapeutic for cancers in women. ..
  21. Genomewide Determinants Of Prognosis And Treatment Of Early-Onset Breast Cancer
    Habibul Ahsan; Fiscal Year: 2010
    ..is disproportionately worse for early-onset cases, who are more likely to be negative for estrogen and progesterone receptors and present with higher grade tumors and advanced stage disease...
  22. Targeting Adenovirus for Gene Therapy of Uterine Leiomyoma
    Ayman Al-Hendy; Fiscal Year: 2013
    ..Additionally it will enhance our understanding of the role of steroid hormones in pathogenesis of uterine fibroids using unique in vivo model systems. ..
  23. Regulation of CD4+ T cell responses by a progesterone receptor
    Grant Hughes; Fiscal Year: 2013
    ....
  24. Exploiting synthetic-lethal interactions to target triple-negative breast cancers
    Dai Horiuchi; Fiscal Year: 2013
    ..overexpress human epidermal growth factor receptor 2 (HER2) and lacks the expression of the estrogen and progesterone receptors. Thus, there is an urgent need in deepening our understanding of this aggressive breast cancer subtype and ..
  25. Regulation of miRNA in breast cancer
    Carolyn M Klinge; Fiscal Year: 2013
    ....
  26. Role of Phospho-Progesterone Receptors (PR) in Hormone Refractory Breast Cancer
    CAROL ANN LANGE; Fiscal Year: 2013
    ..However, progesterone receptors (PR) may also play a key role as mediators of early breast cancer progression...
  27. Implementation of phosphoprotein preservation technology for cancer biospecimens
    LANCE ALLEN LIOTTA; Fiscal Year: 2013
    ..This would increase diagnostic accuracy while substantially reducing costs. ..
  28. Proeolytic Processing of Cyclin E in Breast Cancer
    Khandan Keyomarsi; Fiscal Year: 2013
    ..As such, a targeted and personalized therapy can be justified for those patients who currently do not have such treatment strategies available to them. ..
  29. Non-genomic actions of estrogen in breast cancer
    Ellis R Levin; Fiscal Year: 2013
    ..We identified a conserved 9 amino acid motif in ER?, ER?, and both androgen and progesterone receptors that dictates palmitoylation, resulting in membrane localization of the sex steroid receptors...
  30. Regulation of miRNA expression in breast cancer cells
    CAROLYN KLINGE; Fiscal Year: 2009
    ..It is our long term hope that miRNAs may provide novel biomarkers and new insights into the mechanisms by which breast tumors gain TAM/antiestrogen-resistance and become invasive and metastatic. ..
  31. Rat Models for Sex Steroid Action
    Michael J Soares; Fiscal Year: 2013
    ..These new animal models will be made available to the research community. ..
  32. Progesterone-Induced Gene Expression Changes and Risk of Relapse to Cocaine Use
    Rajita Sinha; Fiscal Year: 2010
    ..Studies in animal models have shown that progesterone receptors are widely expressed in the brain and regulate the expression of a large number of genes in the brains of ..
  33. Estrogen & Progesterone Effects on Orthostatic Tolerance
    NINA STACHENFELD; Fiscal Year: 2010
    ..We also expect that the data in these studies will provide a basis to study the impact of sex hormones on diseases related to compromised peripheral circulation, such as hypertension, Raynaud's phenomenon and diabetes ..
  34. Sex Differences in Musculoskeletal Conditions across the Lifespan
    Nancy E Lane; Fiscal Year: 2013
    ..sex differences in musculoskeletal conditions via: 1) a mechanistic study of sex differences in progesterone receptors that are related to regulation or influence peak bone mass, 2) a prospective clinical cohort study using ..
  35. Role of nuclear progesterone receptors in the control of human parturition
    Sam Mesiano; Fiscal Year: 2013
    ..The research will advance understanding of how progesterone controls human pregnancy and parturition and provide knowledge needed to develop/improve progestin-based therapies to prevent preterm birth. ..
  36. The role of FOXC1 in basal-like breast cancer
    Xiaojiang Cui; Fiscal Year: 2013
    ..Our study will help establish a critical molecular marker for detection and diagnosis of basal-like cancers, and also help uncover the biological basis for the cellular traits and phenotypes of basal-like breast cancer. ..
  37. Antiprogestin therapy for ovarian cancer
    CARLOS MARCELO TELLERIA; Fiscal Year: 2012
    ..cancer cells with particular emphasis on the DNA damage/repair pathways, and will determine whether progesterone receptors are required for the potentiation by antiprogestins of platinum-induced lethality...
  38. STEROID ANTAGONISTS AND RESISTANCE IN BREAST CANCER
    Dean P Edwards; Fiscal Year: 2012
    ..The research in this application will provide insights into the mechanisms and role of PR activation of signaling pathways with the long-term goal of developing pathway selective agents as potential therapeutics. ..
  39. A Narrowed Window for Targeting Metabolic Flexibility in Breast Cancer Prevention
    Pepper J Schedin; Fiscal Year: 2013
    ....
  40. Molecular Analysis of Uterine Receptivity
    FRANCESCO JOHN DEMAYO; Fiscal Year: 2013
    ..PUBLIC HEALTH RELEVANCE: Infertility, endometriosis, and endometrial cancer have a large affect on women's health. This project will determine the role the steroid, progesterone has on these diseases. ..
  41. Targeting FGFR to prevent the outgrowth of metastatic breast cancer
    MICHAEL KEITH WENDT; Fiscal Year: 2013
    ..By definition triple negative breast cancers (TNBC) lack the required targets of hormonal (estrogen and progesterone receptors) and Her2-targeted therapies...
  42. The role of WNT10B and HMGA2 in Lung Metastasis in Triple Negative Breast Cancer
    GUSTAVO ADOLFO MIRANDA-CARBONI; Fiscal Year: 2013
    ..Our findings may alter therapeutics for the metastatic TNBC tumors. ..
  43. NEURAL REGULATION OF PREPARTUM CERVICAL RIPENING
    Steven M Yellon; Fiscal Year: 2013
    ....
  44. Prognostic and predictive gene sets in HER2-positive breast cancer:The HERA Trial
    Brian Leyland Jones; Fiscal Year: 2010
    ....
  45. Deguelin in therapy of triple negative breast cancer
    Rajendra G Mehta; Fiscal Year: 2013
    ....
  46. The optimization of compounds that selectively inhibit protein synthesis for the
    CATHY A SWINDLEHURST; Fiscal Year: 2013
    ....
  47. PROGESTERONE RECEPTOR BINDING TO SPECIFIC DNA SEQUENCES
    Dean P Edwards; Fiscal Year: 2013
    ..The research in this application will provide much needed insight into poorly understood structural and functional properties of PR that is essential for the development of additional and improved SPRMS. ..
  48. CK2-dependent phosphorylation of Progesterone Receptors mediates proliferative si
    Christy Hagan; Fiscal Year: 2013
    ..ck2-dependent activation of PR-B may accelerate mammary tumor development and/or drive early breast cancer progression. ..
  49. Mechanisms of estrogen action on bone marrow-derived stem stromal cells
    Charlotte Kuperwasser; Fiscal Year: 2011
    ..breast cancers that do develop during this time lack appreciable expression of either the estrogen (ER)or progesterone receptors (PR), this suggests that if hormonal changes play a part in promoting breast cancer, they may not be doing ..
  50. Epidemiology of Breast Cancer Subtypes in African American Women: a Consortium
    Julie R Palmer; Fiscal Year: 2013
    ..and to have more aggressive tumors, characterized by high grade, with negative staining for estrogen and progesterone receptors and HER-2 (triple negative)...
  51. Translational Insights into Estrogen Receptor alpha-Positive Luminal Breast Cance
    ROBERT DAVID SCHREIBER; Fiscal Year: 2013
    ..A key feature of this model is that primary tumor cells from these mice- are >90% positive for ER? and progesterone receptors (PR) and show estrogen growth dependency in vitro and in vivo...
  52. Molecular mechanism of LPA3-mediated uterine receptivity
    Xiaoqin Ye; Fiscal Year: 2013
    ....
  53. Identification of novel phytoprogestins from hops and red clover
    Joanna E Burdette; Fiscal Year: 2011
    ..Are phytoprogestins specific and selective for uterine progesterone receptors? Aim 3...
  54. Hormones and Tumor Initiating Cells in Human Breast Cancers
    CAROL ANN SARTORIUS; Fiscal Year: 2013
    ..The latter cells are negative for estrogen and progesterone receptors, and increase several fold in number with progestins, used in birth control and hormone therapy...
  55. Pharmacogenomics of Preterm Birth Prevention and Treatment
    TRACY ANN MANUCK; Fiscal Year: 2013
    ..These advances may result in individualized preterm birth interventions, which in turn could lower the overall rate of both primary and recurrent SPTB and its corresponding neonatal morbidity and mortality. ..
  56. Examining the cell cycle-dependence of progesterone receptor activity
    LINDSEY STARR TREVINO; Fiscal Year: 2013
    ..Investigation of the factors necessary for PR activity may eventually unveil potential therapeutic targets for breast cancer. ..
  57. Caspase-3 Maintains Uterine Quiescence in a PR and NF-Kappa B Dependent Manner
    Jennifer C Condon; Fiscal Year: 2013
    ....
  58. Biomarkers of response to Hsp90 inhibitors in triple-negative breast cancer
    Gabriela Chiosis; Fiscal Year: 2013
    ....
  59. Oral contraceptive use by formulation and breast cancer risk by subtype
    DIANA SM BUIST; Fiscal Year: 2010
    ..This area of research is critical given the high frequency of OC use, heterogeneity of OC formulations, changes in OC formulations over time, and the morbidity and mortality associated with different breast cancer subtypes. ..
  60. Endometriosis and Retinoids
    Serdar E Bulun; Fiscal Year: 2013
    ....
  61. Quantitative Dissection of Steroid Receptor Function
    David L Bain; Fiscal Year: 2013
    ..Cellular occupancy at the promoter will be determined by chromatin immunoprecipitation (ChIP) assays, and the extent of mRNA production will be determined by quantitative RT-PCR. ..
  62. MAINTENANCE AND OPERATION OF A SYNTHETIC PEPTIDE FACILITY
    JEANICK PASCAL; Fiscal Year: 2010
    ..peptide and related contracts and other synthetic chemical contract programs;and (4) radiolabeled synthesis of compounds using 3H, I~C and 1251 for pharmacokinetics and metabolism studies. ..
  63. HETEROGENEITY OF ESTROGEN RECEPTOR STRUCTURE AND ACTION
    Beth Schachter; Fiscal Year: 1993
    ....
  64. SPERM PROGESTERONE RECEPTOR, K+ CHANNEL & PB EXPOSURE
    Asha Jacob; Fiscal Year: 1999
    ..They will determine the stage-specific expression of the human sperm K+ channel by in situ RT/PCR on human testes biopsy sections. ..
  65. Role of the Fetus in the Initiation of Parturition
    CAROLE MENDELSON; Fiscal Year: 2004
    ..abstract_text> ..
  66. NORMAL AND ABNORMAL UTERO-VAGINAL DEVELOPMENT
    Gerald Cunha; Fiscal Year: 1991
    ....
  67. Int5/Aromatase Effect of Breast Estrogen in Neoplasia
    RAJESHWAR TEKMAL; Fiscal Year: 2005
    ..abstract_text> ..
  68. REGULATORY MECHANISMS OF OVARIAN PROGESTERONE RECEPTORS
    Ok Kyong Park Sarge; Fiscal Year: 2000
    ..Her long-term goal is to better understand athe role of ovarian progesterone receptors in the regulation of fertility in normal and dysfunctional reproductive processes...
  69. NOVEL ROLE AND REGULATION OF UTERINE TIMPS
    Warren Nothnick; Fiscal Year: 2000
    ..Dual in-situ hybridization will be used to co- localize the expression of estrogen and progesterone receptors with that of TIMP-1 and TIMP-3 within specific uterine cell-types during the estrous cycle (mature mice) ..
  70. PATHOBIOLOGY OF BREAST CANCER AND HORMONE RECEPTORS
    Michael Press; Fiscal Year: 2003
    ..A retrospective study of HER-2/neu as a predictor of tamoxifen responsiveness is also planned. These studies should lead to a greater understanding of this molecular genetic alteration and its use in clinical management decisions. ..
  71. Mifepristone for Prevention of Breakthrough Bleeding
    John Jain; Fiscal Year: 2004
    ..If Mifepristone is shown to safely decrease the incidence of breakthrough bleeding, more women may continue DMPA and not place themselves at risk of an unintended pregnancy. ..